Gujarat Themis Biosyn Ltd Q2 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/9pprmt3npvjwsc7b6lxml9u2.pdf

Key Takeaways


Capacity & the CAPEX Cycle

Dr. Sachin Patel: "in our past experience there is a significant challenge to scale up. So one may do something at a particular level, starting from lab to even pilot, but then to scale it up to commercial scale and be able to be competitive in terms of the market has its fair set of challenges and experiences required"

Product & Customer Dynamics

Dr. Sachin Patel: "I think on both sides, there are no immediate solutions and that is why relationships are what they are. I would say that we would not have too many options. I would believe that they would not have too many options."

Margin & Pricing

Dr. Sachin Patel: "I wish I could tell you that we can maintain the margins or even grow them. But you know, that would be an indirect way of you asking me what is the pricing going to be tomorrow or day after. So, that will be a bit of a speculation from all our end..."

Competitive Position & Strategy

Dr. Sachin Patel: "I think, for any of us to be complacent and think that there is no potential threat be it from China or anywhere else in terms of pricing or in terms of competition is a bit too complacent."

Demand Outlook & Patent Triggers

Dr. Sachin Patel: "...there is a lot of turmoil that is happening across the world right in terms of currencies, in terms of dollar to the local currency. So sometimes the demand may be there, but because of reasons of debtors, etc, you may have a variation in terms of quantity supply from one quarter to another quarter."

Corporate Developments


Guidance & Commitments

CommitmentSpecificsTimeline
API block commissioningMulti-purpose API block expected onlineEnd of Q2 FY24
Fermentation block construction startThree plants, phased over two to three yearsConstruction starts by December
Fermentation block commissioningFermentation block operationalThe year after the API block
Warehouse capitalizationWarehouse put to useQ3 FY23
R&D center initiationR&D center operational startPostponed to next quarter (Q4 FY23)
NSE listingNet worth criterion of >₹100 cr for 3 consecutive years fulfilledNext year
CAPEX funding₹200 crore funded primarily by internal accruals; debt optionalOver the two-to-three-year CAPEX period

Key Metrics

MetricQ2 FY23
Revenue₹47.69 cr, +36.08% YoY, driven by higher volumes
EBITDA₹24.4 cr, +32.29% YoY
EBITDA margin51.17%, down 146 bps YoY
PAT₹18.7 cr, vs ₹13.79 cr in Q2 FY22
Net profit margin39.21%
EPS₹12.87 per share
H1 FY23 revenue₹92.64 cr, +37.26% YoY, driven by rising volumes
H1 FY23 EBITDA₹47.18 cr, +34.15% YoY
H1 FY23 EBITDA margin50.93%, down 118 bps YoY
H1 FY23 PAT₹36.47 cr, vs ₹26.71 cr in H1 FY22
H1 FY23 net profit margin39.37%
H1 FY23 EPS₹25.10, +36.48% YoY
Capacity utilization95%
CAPEX plan₹200 cr, spread over 2–3 years, funded primarily through internal accruals
CAPEX spent to date~₹22 cr, mostly in CWIP
API plant cost~₹40 cr, expected commissioning end of Q2 FY24